Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans

Clinical Transplantation

Volumn 17, Issue 3, 2003, Pages 206-211

  Emovon, Osemwegie E ^a   King, Judy A C ^a   Op't Holt, Cindy ^a   Singleton, Barbara ^a   Howell, David ^b   Browne, Barry J ^a  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acute rejection; Allograft survival; Cyclosporin pharmacokinetics; Renal transplantation

Indexed keywords

CREATININE; CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; AGE; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG USE; ETHNIC GROUP; FEMALE; GENDER; HIRSUTISM; HUMAN; HYPERTENSION; IMMUNOTHERAPY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MICROEMULSION; NEPHROTOXICITY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECIPIENT; TREATMENT OUTCOME; TREMOR;

ADULT; AFRICAN AMERICANS; AFRICAN CONTINENTAL ANCESTRY GROUP; AREA UNDER CURVE; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MYCOPHENOLIC ACID; PREDNISONE;

EID: 0038678031     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0012.2003.00029.x     Document Type: Article

References (19)

1. Butkus DE, Meydrech EF, Raju SS. Racial differences in the survival of cadeveric renal allografts. Overiding effects of HLA matching and socioeconomic factors. N Engl J Med 1992: 327: 840.
2. Hariharan S, Schroeder TJ, First MR. Effect of race on renal transplant outcome. Clin Transplant 1993: 7: 235.
3. Takemoto S, Terasaki PI. A comparison of kidney transplant survival in white and black recipients. Transplant Proc 1989: 21: 3865.
4. Ojo AO, Port FK, Held PJ et al. Inferior outcome of two-haplotype matched renal transplants in blacks: role of early rejection. Kidney Int 1995: 48: 1592.
5. Meier-Kriesche HU, Ojo A, Magee JC et al. African-American renal transplant recipients experience decreased risk of death due to infection: possible implications for immunosuppressive strategies. Transplantation 2000:70: 375.
6. Emovon OE, Op't Holt C, Browne BJ. Can a pharmacokinetic approach to immunosuppression eliminate ethnic disparities in renal allograft outcome. Clin Transplant 2002: 16 (Suppl. 7): 45.
7. Mahalati K, Belitsky P, Sketris I, West K, Panek R. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 1999: 68: 55.
8. Amante A, Kahan BD. Abbreviated area-under-the-curve strategy for monitoring cyclosporine microemulsion therapy in immediate posttransplant period. Clin Chem 1996: 42: 1294.
9. Flechner SM, Mondin CS, Serrano DP et al. Determinants of chronic rejection in cyclosporine-treated recipients. Transplantation 1996: 62: 1235.
10. Smith SR, Butterly DW. Declining influence of race on the outcome of living-donor renal transplantation. Am J Transplant 2002: 2: 282.
11. Browne BJ, Op't Holt C, Emovon OE. Diurnal cyclosporine dosing optimizes exposure and reduces the risk of acute rejection after kidney transplantation. Clin Transplant 2001: 15 (Suppl.): 51.
12. Heifets M, Cooney GF, Shaw LM, Libetti G. Diurnal variation of cyclosporine clearance in stable renal transplant recipients receiving continuous infusion. Transplantation 1995: 60: 1615.
13. Cipolle RJ, Canafax DM, Rabatin J, Bowers LD, Sutherland DE, Hrushesky WJ. Time-dependent disposition of cyclosporine after pancreas transplantation, and application of chronopharmacokinetics to improve immunosuppression. Pharmacotherapy 1988: 8: 47.
14. Ohlman S, Lindholm A, Hagglund H, Sawe J, Kahan BD. On the intraindividual variability and chronobiology of cyclosporine pharmacokinetics in renal transplantation. Eur J Clin Pharmacol 1993: 44: 265.
15. Kahan BD, Grevel J. Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation 1988: 5: 631.
16. Mahalati K, Lawen J, Kiberd B, Belitsky P. Is 3-hour cyclosporine blood level superior to trough level in early post-renal transplantation period? J Urol 2000: 163: 37.
17. Mahalati K, Belitsky P, West K et al. Approaching the therapeutic window for cyclosporine in kidney transplantation: a prospective study. J Am Soc Nephrol 2001: 12: 828.
18. International Neoral Renal Transplantation Study Group. Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplantation 2002: 2: 148.
19. International Neoral Renal Transplantation Study Group. Randomized, international study of cyclosporine microemulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis. Am J Transplant 2002: 2: 157.